Literature DB >> 27981451

Bromelain-Functionalized Multiple-Wall Lipid-Core Nanocapsules: Formulation, Chemical Structure and Antiproliferative Effect Against Human Breast Cancer Cells (MCF-7).

Catiúscia P Oliveira1,2, Willian A Prado3, Vladimir Lavayen3, Sabrina L Büttenbender3, Aline Beckenkamp4, Bruna S Martins3, Diogo S Lüdtke3, Leandra F Campo3, Fabiano S Rodembusch3, Andréia Buffon4, Adalberto Pessoa5, Silvia S Guterres4, Adriana R Pohlmann6,7,8.   

Abstract

PURPOSE: This study was conducted a promising approach to surface functionalization developed for lipid-core nanocapsules and the merit to pursue new strategies to treat solid tumors.
METHODS: Bromelain-functionalized multiple-wall lipid-core nanocapsules (Bro-MLNC-Zn) were produced by self-assembling following three steps of interfacial reactions. Physicochemical and structural characteristics, in vitro proteolytic activity (casein substrate) and antiproliferative activity (breast cancer cells, MCF-7) were determined.
RESULTS: Bro-MLNC-Zn had z-average diameter of 135 nm and zeta potential of +23 mV. The complex is formed by a Zn-N chemical bond and a chelate with hydroxyl and carboxyl groups. Bromelain complexed at the nanocapsule surface maintained its proteolytic activity and showed anti-proliferative effect against human breast cancer cells (MCF-7) (72.6 ± 1.2% at 1.250 μg mL-1 and 65.5 ± 5.5% at 0.625 μg mL-1). Comparing Bro-MLNC-Zn and bromelain solution, the former needed a dose 160-folds lower than the latter for a similar effect. Tripan blue dye assay corroborated the results.
CONCLUSIONS: The surface functionalization approach produced an innovative formulation having a much higher anti-proliferative effect than the bromelain solution, even though both in vitro proteolytic activity were similar, opening up a great opportunity for further studies in nanomedicine.

Entities:  

Keywords:  MCF-7 human breast cancer cells; bromelain; lipid-core nanocapsules; metal-chitosan complex; surface-functionalized nanoparticles

Mesh:

Substances:

Year:  2016        PMID: 27981451     DOI: 10.1007/s11095-016-2074-2

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  31 in total

1.  Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.

Authors:  José Baselga; Mario Campone; Martine Piccart; Howard A Burris; Hope S Rugo; Tarek Sahmoud; Shinzaburo Noguchi; Michael Gnant; Kathleen I Pritchard; Fabienne Lebrun; J Thaddeus Beck; Yoshinori Ito; Denise Yardley; Ines Deleu; Alejandra Perez; Thomas Bachelot; Luc Vittori; Zhiying Xu; Pabak Mukhopadhyay; David Lebwohl; Gabriel N Hortobagyi
Journal:  N Engl J Med       Date:  2011-12-07       Impact factor: 91.245

2.  Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill.

Authors:  M B Hansen; S E Nielsen; K Berg
Journal:  J Immunol Methods       Date:  1989-05-12       Impact factor: 2.303

3.  Impact of complementary oral enzyme application on the postoperative treatment results of breast cancer patients--results of an epidemiological multicentre retrolective cohort study.

Authors:  J Beuth; B Ost; A Pakdaman; E Rethfeldt; P R Bock; J Hanisch; B Schneider
Journal:  Cancer Chemother Pharmacol       Date:  2001-07       Impact factor: 3.333

4.  Bromelain inhibits nuclear factor kappa-B translocation, driving human epidermoid carcinoma A431 and melanoma A375 cells through G(2)/M arrest to apoptosis.

Authors:  Kulpreet Bhui; Shilpa Tyagi; Amit Kumar Srivastava; Madhulika Singh; Preeti Roy; Richa Singh; Yogeshwer Shukla
Journal:  Mol Carcinog       Date:  2011-03-22       Impact factor: 4.784

Review 5.  Poly(ϵ-caprolactone) microcapsules and nanocapsules in drug delivery.

Authors:  Adriana Raffin Pohlmann; Francisco Noe Fonseca; Karina Paese; Cassia Britto Detoni; Karine Coradini; Ruy Cr Beck; Silvia S Guterres
Journal:  Expert Opin Drug Deliv       Date:  2013-02-07       Impact factor: 6.648

Review 6.  Targeting the PI3K/AKT/mTOR pathway in estrogen receptor-positive breast cancer.

Authors:  Eva Maria Ciruelos Gil
Journal:  Cancer Treat Rev       Date:  2014-03-26       Impact factor: 12.111

7.  Anticancer effect of bromelain with and without cisplatin or 5-FU on malignant peritoneal mesothelioma cells.

Authors:  Krishna Pillai; Anahid Ehteda; Javid Akhter; Terence C Chua; David L Morris
Journal:  Anticancer Drugs       Date:  2014-02       Impact factor: 2.248

8.  Regulation of p53, nuclear factor kappaB and cyclooxygenase-2 expression by bromelain through targeting mitogen-activated protein kinase pathway in mouse skin.

Authors:  Neetu Kalra; Kulpreet Bhui; Preeti Roy; Smita Srivastava; Jasmine George; Sahdeo Prasad; Yogeshwer Shukla
Journal:  Toxicol Appl Pharmacol       Date:  2007-08-23       Impact factor: 4.219

9.  Cytotoxic effects of bromelain in human gastrointestinal carcinoma cell lines (MKN45, KATO-III, HT29-5F12, and HT29-5M21).

Authors:  Afshin Amini; Anahid Ehteda; Samar Masoumi Moghaddam; Javed Akhter; Krishna Pillai; David Lawson Morris
Journal:  Onco Targets Ther       Date:  2013-04-16       Impact factor: 4.147

10.  Long-term remission of a Her2/neu positive primary breast cancer under double monoclonal antibody therapy with trastuzumab and bevacizumab.

Authors:  Robert Königsberg; Julia Maierhofer; Tanja Steininger; Gabriele Kienzer; Christian Dittrich
Journal:  Radiol Oncol       Date:  2014-04-25       Impact factor: 2.991

View more
  8 in total

1.  Folic Acid-Doxorubicin-Double-Functionalized-Lipid-Core Nanocapsules: Synthesis, Chemical Structure Elucidation, and Cytotoxicity Evaluation on Ovarian (OVCAR-3) and Bladder (T24) Cancer Cell Lines.

Authors:  Rodrigo Cé; Vladimir Lavayen; Gabriela Klein Couto; João Guilherme Barreto De Marchi; Barbara Zoche Pacheco; Letícia Antunes Natividade; Tiago Ost Fracari; Taiane Medeiro Ciocheta; Aline de Cristo Soares Alves; Denise Soledade Jornada; Silvia Stanisçuaski Guterres; Fabiana Seixas; Tiago Collares; Adriana Raffin Pohlmann
Journal:  Pharm Res       Date:  2021-02-19       Impact factor: 4.200

2.  Bromelain Loaded Lipid-Polymer Hybrid Nanoparticles for Oral Delivery: Formulation and Characterization.

Authors:  Mahboubeh Ebrahimian; Fatemeh Mahvelati; Bizhan Malaekeh-Nikouei; Ezzat Hashemi; Fatemeh Oroojalian; Maryam Hashemi
Journal:  Appl Biochem Biotechnol       Date:  2022-05-04       Impact factor: 3.094

Review 3.  Plant-Derived Natural Products in Cancer Research: Extraction, Mechanism of Action, and Drug Formulation.

Authors:  Wamidh H Talib; Izzeddin Alsalahat; Safa Daoud; Reem Fawaz Abutayeh; Asma Ismail Mahmod
Journal:  Molecules       Date:  2020-11-14       Impact factor: 4.411

4.  In vitro performance of free and encapsulated bromelain.

Authors:  Janaína Artem Ataide; Letícia Caramori Cefali; Mariana Cecchetto Figueiredo; Lúcia Elaine de Oliveira Braga; Ana Lúcia Tasca Gois Ruiz; Mary Ann Foglio; Laura Oliveira-Nascimento; Priscila Gava Mazzola
Journal:  Sci Rep       Date:  2021-05-13       Impact factor: 4.379

5.  Enhanced and Selective Antiproliferative Activity of Methotrexate-Functionalized-Nanocapsules to Human Breast Cancer Cells (MCF-7).

Authors:  Catiúscia P de Oliveira; Sabrina L Büttenbender; Willian A Prado; Aline Beckenkamp; Ana C Asbahr; Andréia Buffon; Silvia S Guterres; Adriana R Pohlmann
Journal:  Nanomaterials (Basel)       Date:  2018-01-04       Impact factor: 5.076

6.  Arginylglycylaspartic Acid-Surface-Functionalized Doxorubicin-Loaded Lipid-Core Nanocapsules as a Strategy to Target Alpha(V) Beta(3) Integrin Expressed on Tumor Cells.

Authors:  Michelli B Antonow; Camila Franco; Willian Prado; Aline Beckenkamp; Gustavo P Silveira; Andréia Buffon; Sílvia S Guterres; Adriana R Pohlmann
Journal:  Nanomaterials (Basel)       Date:  2017-12-22       Impact factor: 5.076

7.  An Inhalable Powder Formulation Based on Micro- and Nanoparticles Containing 5-Fluorouracil for the Treatment of Metastatic Melanoma.

Authors:  Kelly Cristine Zatta; Luiza A Frank; Luciano Antonio Reolon; Lucas Amaral-Machado; Eryvaldo S T Egito; Maria Palmira Daflon Gremião; Adriana Raffin Pohlmann; Silvia S Guterres
Journal:  Nanomaterials (Basel)       Date:  2018-01-30       Impact factor: 5.076

8.  Oral Treatment of Spontaneously Hypertensive Rats with Captopril-Surface Functionalized Furosemide-Loaded Multi-Wall Lipid-Core Nanocapsules.

Authors:  Cecilia B Michalowski; Marcelo D Arbo; Louise Altknecht; Andréia N Anciuti; Angélica S G Abreu; Luciana M R Alencar; Adriana R Pohlmann; Solange C Garcia; Sílvia S Guterres
Journal:  Pharmaceutics       Date:  2020-01-18       Impact factor: 6.321

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.